The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Interim analysis of a phase I/Ib study of enfortumab vedotin plus cabozantinib in patients with metastatic urothelial carcinoma.
 
Jacqueline T Brown
Honoraria - Curio/Vaniam Group
Research Funding - Medicenna (Inst); Surface Oncology (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Curio/Vaniam Group
 
Bassel Nazha
Honoraria - Intellisphere, LLC (Onclive)
Consulting or Advisory Role - Cardinal Health; Exelixis; IntrinsiQ
 
Yuan Liu
No Relationships to Disclose
 
Shreya Ranbhise
No Relationships to Disclose
 
Kelsea Lozada
No Relationships to Disclose
 
Caitlin Hartman
No Relationships to Disclose
 
Greta Russler McClintock
No Relationships to Disclose
 
Omer Kucuk
No Relationships to Disclose
 
Bradley Curtis Carthon
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Gilead Sciences; Immunomedics
Research Funding - Alkermes (Inst); MedImmune (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
R. Donald Harvey
Consulting or Advisory Role - Amgen; Erasca, Inc; Janssen Oncology
Research Funding - Abbisko (Inst); Abbvie (Inst); ADC Therapeutics; GlaxoSmithKline (Inst); Incyte; Janssen Research & Development (Inst); Merck (Inst); Meryx Pharmaceuticals (Inst); MorphoSys; Nektar (Inst); Takeda (Inst); Xencor (Inst)
 
Mehmet Asim Bilen
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Exelixis; Genomic Health; Janssen; Nektar; Pfizer; Sanofi; SeaGen
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genome & Company (Inst); Incyte (Inst); Merck (Inst); Nektar (Inst); NiKang Therapeutics (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst); Xencor (Inst)